Key Points
- Arcus Biosciences CAO Alexander Azoy sold 2,562 shares on June 1 at an average price of $25.77, totaling about $66,023. The transaction was made under a pre-arranged Rule 10b5-1 plan, and he still holds 39,581 shares worth roughly $1.02 million.
- RCUS shares were up about 1.6% and opened at $25.74, trading near the stock’s 52-week high of $28.72. The company has a market cap of about $3.24 billion and a relatively strong liquidity position, with a current ratio of 4.04.
- Recent fundamentals were weak: Arcus reported a quarterly loss of $1.02 per share, missing analyst expectations, and revenue of $17 million versus the $29.49 million forecast. Analysts currently rate the stock a Moderate Buy on average, with a consensus target price of $33.89.
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 2,562 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the transaction, the chief accounting officer directly owned 39,581 shares of the company's stock, valued at approximately $1,020,002.37. This trade represents a 6.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arcus Biosciences Trading Up 1.6%
Shares of RCUS stock opened at $25.74 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The firm has a market cap of $3.24 billion, a PE ratio of -8.10 and a beta of 0.87. The company has a 50-day moving average of $23.61 and a two-hundred day moving average of $22.73. Arcus Biosciences, Inc. has a 1-year low of $7.91 and a 1-year high of $28.72.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The company had revenue of $17.00 million for the quarter, compared to analysts' expectations of $29.49 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The company's quarterly revenue was down 39.3% compared to the same quarter last year. During the same period last year, the business earned ($1.14) EPS. On average, analysts predict that Arcus Biosciences, Inc. will post -3.54 EPS for the current year.
Wall Street Analyst Weigh In
RCUS has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of Arcus Biosciences in a report on Monday, March 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcus Biosciences in a report on Monday, April 20th. The Goldman Sachs Group raised their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Wells Fargo & Company set a $23.00 price objective on shares of Arcus Biosciences and gave the company an "equal weight" rating in a research report on Thursday, February 12th. Finally, Wedbush lifted their price objective on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, April 2nd. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $33.89.
Get Our Latest Research Report on RCUS
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in RCUS. AQR Capital Management LLC raised its stake in Arcus Biosciences by 253.9% in the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company's stock valued at $714,000 after purchasing an additional 65,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Arcus Biosciences by 10.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company's stock worth $297,000 after purchasing an additional 3,565 shares during the period. Millennium Management LLC grew its holdings in shares of Arcus Biosciences by 29.2% during the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company's stock worth $9,378,000 after purchasing an additional 270,253 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Arcus Biosciences by 106.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company's stock worth $7,177,000 after acquiring an additional 470,755 shares during the period. Finally, Strs Ohio purchased a new position in Arcus Biosciences in the 1st quarter worth approximately $67,000. Institutional investors and hedge funds own 92.89% of the company's stock.
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.
The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
